Andrew Menzies-Gow, ERS 2021: Benralizumab Following Oral Corticosteroid Reduction in Severe Asthma
TouchRESPIRATORY got the opportunity to catch up with Professor Andrew Menzies-Gow (Royal Brompton Hospital and Imperial College London, London, UK) to discuss oral corticosteroid (OCS) dependency in severe asthma and the use of benralizumab following OCS reduction.
The abstract ‘Durable clinical benefit of benralizumab following oral corticosteroid reduction: The PONENTE study.’ (ID:1460) was presented at ERS International Congress 2021, 5-8 September 2021.
- How much of a problem is OCS dependency in severe asthma? (0:12)
- Could you tell us a little about the PONENTE study and its findings to date? (0:45)
- What are the implications of these findings for the severe asthma treatment landscape? (1:58)
- What will be the next steps in your research? (2:46)
Disclosures: Andrew Menzies-Gow discloses attending advisory boards for Astra Zeneca, Sanofi, Novartis and Glaxo SmithKline; Receiving speaker fees from AZ, Novartis, Teva and Sanofi; and has participated in research with AZ.
Support: Interview and filming supported by Touch Medical Media. Interview conducted by Victoria Jones.
Filmed as a highlight of ERS 2021 (Virtual).
Share this Video
Related Videos In Asthma
Isaac Schmale, AAAAI 2023: Efficacy of dupilumab for nasal polyposis in patients with aspirin-exacerbated respiratory disease
Dupilumab is used to manage chronic rhinosinusitis with nasal polyposis, however there is limited data regarding its use in patients with aspirin-exacerbated respiratory disease (AERD). touchRESPIRATORY caught up with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the aims, eligibility, methodology and findings of his study investigating the real-world outcomes of […]
Isaac Schmale, AAAAI 2023: Signs and symptoms of aspirin-exacerbated respiratory disease and its treatment paradigm
touchRESPIRATORY were delighted to speak with Dr Isaac Schmale (University of Rochester Medical Center, Rochester, NY, USA) around the signs and symptoms of aspirin-exacerbated respiratory disease (AERD), the incidence of AERD in people with asthma, the current treatment paradigm for AERD and the unmet needs in its treatment. The abstract ‘Real-world Outcomes of Dupilumab Therapy […]
Ronald Strauss, AAAAI 2023: Hot topics to explore in the field of respiratory medicine
touchRESPIRATORY were delighted to speak with a valued member of our Editorial Board for touchREVIEWS in Respiratory & Pulmonary Diseases, Dr Ronald Strauss (Case Western Reserve University; Cleveland Allergy and Asthma Center, Cleveland, OH, USA), about the areas in the field of respiratory medicine that he is most looking forward to exploring in 2023. Questions […]
Journal articles and more to your inbox
Get the latest clinical insights from touchRESPIRATORYSign me up!